Fuji Pharma
4554.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2025-09 | 2024-09 | 2023-09 | 2022-09 | 2021-09 | 2020-09 |
|---|---|---|---|---|---|---|
| Revenue | ¥51.7bn | ¥46.1bn | ¥40.9bn | ¥35.4bn | ¥34.0bn | ¥33.8bn |
| Operating income | ¥5.0bn | ¥3.9bn | ¥3.9bn | ¥3.8bn | ¥3.3bn | — |
| Ordinary income | ¥4.5bn | ¥4.4bn | ¥4.5bn | ¥3.7bn | ¥3.3bn | ¥3.0bn |
| Net income (owners) | ¥3.0bn | ¥6.1bn | ¥3.4bn | ¥2.7bn | ¥2.4bn | ¥2.1bn |
| Total assets | ¥93.4bn | ¥90.0bn | ¥85.3bn | ¥75.5bn | ¥64.2bn | ¥62.0bn |
| Net assets / equity | ¥46.9bn | ¥45.6bn | ¥41.2bn | ¥35.8bn | ¥32.7bn | ¥40.0bn |
| Operating cash flow | ¥5.8bn | ¥4.2bn | ¥1.9bn | −¥658m | ¥6.0bn | ¥5.8bn |
| EPS (basic) | ¥122.94 | ¥252.85 | ¥141.37 | ¥111.01 | ¥90.54 | ¥66.94 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-10-01 → 2026-03-31 | Half-year | 67 figures · EDINET |
| 2024-10-01 → 2025-09-30 | Annual | 196 figures · EDINET |
| 2024-10-01 → 2025-03-31 | Half-year | 67 figures · EDINET |
| 2023-10-01 → 2024-09-30 | Annual | 196 figures · EDINET |
| 2023-10-01 → 2024-03-31 | Quarterly Q2 | 69 figures · EDINET |
| 2023-10-01 → 2023-12-31 | Quarterly Q1 | 43 figures · EDINET |
| 2022-10-01 → 2023-09-30 | Annual | 196 figures · EDINET |
| 2022-10-01 → 2023-06-30 | Quarterly Q3 | 45 figures · EDINET |
| 2022-10-01 → 2023-03-31 | Quarterly Q2Amended | 69 figures · EDINET |
| 2022-10-01 → 2023-03-31 | Quarterly Q2 | 69 figures · EDINET |
| 2022-10-01 → 2022-12-31 | Quarterly Q1 | 43 figures · EDINET |
| 2021-10-01 → 2022-09-30 | Annual | 196 figures · EDINET |
| 2021-10-01 → 2022-06-30 | Quarterly Q3 | 45 figures · EDINET |
22 more reports are still being processed.